

1 **LOWEY DANNENBERG, P.C.**
2 Christian Levis (admitted *pro hac vice*)
3 Amanda Fiorilla (admitted *pro hac vice*)
4 Rachel Kesten (admitted *pro hac vice*)
5 44 South Broadway, Suite 1100
6 White Plains, NY 10601
7 Telephone: (914) 997-0500
8 Facsimile: (914) 997-0035
9 E-Mail: clevis@lowey.com
10 afiorilla@lowey.com
11 rkesten@lowey.com

12 **BURSOR & FISHER, P.A.**
13 L. Timothy Fisher (State Bar No. 191626)
14 Jenna L. Gavenman (State Bar No. 348510)
15 1990 North California Blvd., Suite 940
16 Walnut Creek, CA 94596
17 Telephone: (925) 300-4455
18 Facsimile: (925) 407-2700
19 E-Mail: ltfisher@bursor.com
20 jgavenman@bursor.com

21 *Interim Co-Lead Class Counsel*

22 **UNITED STATES DISTRICT COURT**
23 **NORTHERN DISTRICT OF CALIFORNIA**

24 JANE DOE, et al., individually and on behalf of
25 all others similarly situated,

26 Plaintiffs,

27 v.

28 GOODRX HOLDINGS, INC., et al.,

Defendants.

Case No. 3:23-cv-00501-AMO

**PLAINTIFFS' REPLY ON MOTION
FOR ORDER ENJOINING
DEFENDANT GOODRX FROM
FURTHER VIOLATING COURT
ORDER**

Date: December 14, 2023

Time: 2:00 p.m.

Courtroom: 10

Hon. Araceli Martínez-Olguín

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
TABLE OF CONTENTS

PAGE(S)

I.	INTRODUCTION	1
II.	ADDITIONAL FACTUAL BACKGROUND.....	2
III.	AN INJUNCTION UNDER THE ALL WRITS ACT IS WARRANTED.....	3
IV.	THIS IS NOT A CASE OF PARALLEL LITIGATION.....	6
V.	GOODRX WAS COMPELLED TO NEGOTIATE SETTLEMENT WITH INTERIM CLASS COUNSEL.....	8
VI.	AN INJUNCTION IS NECESSARY TO PRESENT IRREPARABLE HARM	9
VII.	THE <i>HODGES</i> SETTLEMENT IS NOT FAIR AND REASONABLE.....	10
A.	GoodRx Lied to This Court to Delay Court-Ordered Mediation	11
B.	GoodRx Simultaneously Pursued Mediation with <i>Hodges</i> Counsel.....	11
C.	GoodRx & Milberg's Mediation Was Designed to Quickly Resolve the Class's Claims Without Engaging in Informed Discussions.....	12
D.	The Settlement is Untethered to GoodRx's Liability	13
E.	GoodRx & Milberg Violated the Local Rules to Obtain Preliminary Approval	13
	CONCLUSION	14

1 TABLE OF AUTHORITIES
23 **PAGE(S)**4 **CASES**

5	<i>Alltrade, Inc. v. Uniweld Prods., Inc.</i> , 946 F.2d 622 (9th Cir. 1991).....	9
6	<i>Grider v. Keystone Health Plan Cent., Inc.</i> , 500 F.3d 322 (3d Cir. 2007).....	8
7	<i>Hansell v. TracFone Wireless, Inc.</i> , 2013 WL 6155618 (N.D. Cal. Nov. 22, 2013).....	8
9	<i>In re Am. Online Spin-Off Accts. Litig.</i> , 2005 WL 5747463 (C.D. Cal. May 9, 2005).....	4
10	<i>In re Bank of Am. Wage & Hour Emp. Litig.</i> , 740 F. Supp. 2d 1207 (D. Kan. 2010)	4, 9
11	<i>In re Bluetooth Headset Prod. Liab. Litig.</i> , 654 F.3d 935 (9th Cir. 2011).....	13
12	<i>In re Checking Acct. Overdraft Litig.</i> , 859 F. Supp. 2d 1313 (S.D. Fla. 2012).....	4, 5
13	<i>In re Life Invs. Ins. Co. of Am.</i> , 589 F.3d 319 (6th Cir. 2009).....	8
14	<i>In re Managed Care Litig.</i> , 236 F. Supp. 2d 1336 (S.D. Fla. 2002).....	passim
15	<i>Kabasele v. Ulta Salon, Cosms. & Fragrance, Inc.</i> , 2023 WL 2918679 (E.D. Cal. Apr. 12, 2023)	13
16	<i>Kiland v. Bos. Sci. Corp.</i> , 2011 WL 1261130 (N.D. Cal. Apr. 1, 2011).....	5
17	<i>Mandel v. Grande Cosms., LLC</i> , 2023 WL 7109893 (N.D. Cal. Oct. 27, 2023)	7
18	<i>Manuel v. Convergys Corp.</i> , 430 F.3d 1132 (11th Cir. 2005).....	8
19	<i>Negrete v. Allianz Life Ins. Co. of N. Am.</i> , 523 F.3d 1091 (9th Cir. 2008)	7
20	<i>Oceana Seafood Prod., LLC v. Louisiana Newpack Shrimp Co.</i> , 2020 WL 13880993 (S.D. Fla. Dec. 31, 2020).....	8

1	<i>Pacesetter Sys., Inc. v. Medtronic, Inc.</i> , 678 F.2d 93 (9th Cir. 1982).....	9
2		
3	<i>Perkins v. Am. Nat. Ins. Co.</i> , 446 F. Supp. 2d 1350 (M.D. Ga. 2006)	4
4		
5	<i>Primo v. Pac. Biosciences of California, Inc.</i> , 2013 WL 4482739 (N.D. Cal. Aug. 20, 2013).....	7
6		
7	<i>Saleh v. Titan Corp.</i> , 353 F. Supp. 2d 1087 (S.D. Cal. 2004)	7
8		
9	<i>Salmonson v. Bed Bath & Beyond, Inc.</i> , 2012 WL 12919187 (C.D. Cal. Apr. 27, 2012).....	8
10		
11	STATUTES	
12	28 U.S.C. § 1404	6
13	28 U.S.C. § 1407	6
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		

1 **I. INTRODUCTION**

2 The All Writs Act is a backstop on the powers of Federal courts. It exists precisely for
 3 circumstances like this: where dishonest conduct falling outside the remedies available under the
 4 Federal Rules would deprive the court of jurisdiction if allowed to continue. Indeed, it is difficult to
 5 imagine a more exigent circumstance than this one. GoodRx violated the rules in two Federal districts
 6 at least three times to ram through a settlement it reached with a group of individuals that never filed
 7 an action and whose interests were directly antagonistic to those of class. GoodRx negotiated this
 8 deal in secret, repeatedly misrepresenting to this Court and Interim Class Counsel that it had no
 9 interest in resolving those claims. This wasted countless hours and judicial resources on unnecessary
 10 discovery and motion practice. GoodRx then signed off on a motion for approval of that settlement
 11 in Florida as “unopposed” knowing it had never met-and-conferred with Interim Class Counsel, or
 12 even mentioned that settlement to them. The Florida court was also left in the dark as neither GoodRx
 13 nor their counterparts at Milberg bothered to inform it of this action prior to any of their filings.

14 Courts faced with similar shady dealings recognize they are not passive observers at a parade
 15 of horrors because the All Writs Act empowers them to curb “underhanded maneuvers” and ensure
 16 the “proper administration of justice.” *In re Managed Care Litig.*, 236 F. Supp. 2d 1336, 1342-43
 17 (S.D. Fla. 2002). GoodRx attempts to wrench that authority from the Court’s hands by proclaiming
 18 its good intentions, the virtues of the settlement, and other instances where “parallel actions” have
 19 proceeded in tandem and settled separately. This is nonsense. There are simply too many indicia of
 20 bad faith on top of rule violations to believe GoodRx. The Florida settlement is embarrassing,
 21 recouping just 0.013% of GoodRx’s potential liability. And the comparisons to “parallel actions” are
 22 inept given that *Hodges* was settled *before it was filed* and never litigated alongside this case.

23 Perhaps recognizing these errors, GoodRx and Milberg have since moved to stay the
 24 *Hodges*’s settlement deadlines pending mediation here. That is a start, but it is not enough. This
 25 Court should stay the *Hodges* action so it can be transferred to this district where it belongs. Interim
 26 Class Counsel can then focus on litigating or obtaining an appropriate resolution on behalf of the
 27 class they were appointed to represent.

1 **II. ADDITIONAL FACTUAL BACKGROUND**

2 Plaintiffs' Opening Brief ("Opening Br.") outlined the facts warranting an order under the
 3 All Writs Act. *See* Opening Br., ECF No. 151 at 1-3. The section below concerns new developments
 4 since Plaintiffs filed that motion and responds to certain inaccuracies in GoodRx's counterstatement
 5 of facts.

6 **A. GoodRx First Represented in May that Settlement Efforts Were Premature**

7 GoodRx spends considerable time arguing that it did not misrepresent its position on
 8 settlement because the parties collectively agreed in joint statements that discussions would be
 9 premature. *See* GoodRx's Opposition to Plaintiffs' Motion to Enjoin ("Opp."), ECF No. 164 at 3-4.
 10 This omits a key fact. Four days before a conference with the mediator on May 22, 2023, GoodRx
 11 contacted Interim Class Counsel to advocate in favor of delaying mediation, because it believed
 12 settlement discussions were premature until after their motions to dismiss and compel arbitration
 13 were fully briefed. Declaration of A. Fiorilla ("Fiorilla Decl.") ¶ 5. While Interim Class Counsel
 14 stated they were open to mediation, (*id.*) they ultimately agreed to the parties' joint statement based
 15 on GoodRx's representation that mediation would be wasteful at that time.

16 **B. GoodRx Could Have Invited Interim Class Counsel to the Mediation**

17 On November 13, 2023, Interim Class Counsel learned for the first time, that GoodRx and
 18 Milberg held their first mediation on July 13, 2023. *See* Declaration of Martin L. Roth in Support's
 19 GoodRx's Opposition, ECF No. 165 ¶ 5. This was 6 days after Interim Class Counsel were appointed.
 20 As stated at the Order to Show Cause hearing, GoodRx and Interim Class Counsel were on a call at
 21 the time the Court issued its appointment order. *See* Fiorilla Decl. ¶ 7. GoodRx acknowledged and
 22 even congratulated counsel on their appointment. *Id.* With a week to spare, nothing prevented
 23 GoodRx from inviting Interim Class Counsel to represent the class at that mediation, other than a
 24 desire to ensure the class was not represented.

25 **C. GoodRx Has Since Sought to Stay the Florida Action**

26 GoodRx filed a "Notice Regarding Compliance" with the settlement in the *Hodes* action on
 27 November 16, 2023, touting how it has sent notice of the settlement to state and federal officials,

1 deposited an initial amount into the Settlement Fund, and is “working toward the class notice
 2 deadline.” *Hedges* Action, ECF No. 24 at 1. However, yesterday evening, GoodRx and Milberg filed
 3 an unopposed motion to stay the pending settlement deadlines until mediation can occur in this action
 4 before Judge James in early January. *See* Fiorilla Decl., Ex. A. This sudden about face is telling: if
 5 even GoodRx and Milberg recognize that a stay in Florida is warranted this Court should have no
 6 trouble granting the relief Plaintiffs requested.

7 **III. AN INJUNCTION UNDER THE ALL WRITS ACT IS WARRANTED**

8 The exigencies here are palpable. Working in secret to avoid court-ordered mediation,
 9 GoodRx managed to buy a release for the claims in this action from a group of individuals who never
 10 filed a case. The price (\$0.78 per person, before fees and expenses) was arbitrarily set by counsel
 11 who did not represent *any* class, after zero due-diligence (oddly, the settlement approval papers make
 12 no mention of any discovery efforts). *See* Opening Br. at 6; *see also* ECF No. 151-2. The *Hedges*
 13 action—which was settled before it began—was initiated solely as the vehicle to deprive this court
 14 of jurisdiction through approval of that settlement. Allowing the *Hedges* action to proceed would
 15 ratify the rule violations, misrepresentation, and surreptitious dealings leading up to this point. *See*
 16 Opening Br. at 4-6.

17 There is no reason that should occur. Faced with nearly identical conduct, courts have utilized
 18 the All Writs Act to quash improper attempts to settle claims in consolidated cases out from under
 19 the Class. For instance, in *Managed Care*, 236 F. Supp. 2d at 1339, where cases were consolidated
 20 and proceeding in the Southern District of Florida, defendant entered a settlement with plaintiffs who
 21 sought preliminary approval the following day in the Southern District of Illinois. Defendant and the
 22 Illinois plaintiffs “did not reveal” to the Illinois court that the settlement encompassed claims from
 23 the consolidated Florida action, and (like here) succeeded in obtaining preliminary approval that
 24 same day. *Id.*

25 Once alerted to defendant’s attempt to settle the class’s claims outside the consolidated
 26 proceedings, the Florida court admonished the defendant who “snookered both [that] Court and the
 27 [court] in Illinois in an obvious attempt to avoid this Court’s jurisdiction.” *Id.* at 1342. The court

1 found it “incredulous” that the defendant could “with a straight face, argue to this Court that its
 2 maneuvering is agreeable to the usages and principles of law” simply because settlements are
 3 *generally* preferable. *Id.* To curb defendant’s “underhanded maneuvers” and ensure the “proper
 4 administration of justice,” the Florida court utilized the All Writs Act to enjoin the defendant from
 5 moving forward with the settlement. *Id.* at 1342-43.

6 *Perkins v. Am. Nat. Ins. Co.*, 446 F. Supp. 2d 1350, 1352 (M.D. Ga. 2006) is another example
 7 where a court invoked the All Writs Act to rectify a similar settlement. There, the plaintiff sought an
 8 injunction after the defendant sought to settle the class’s claims in a later filed action without any
 9 notice to plaintiff or his counsel. *Id.* The *Perkins* court ordered defendant to file a motion to stay in
 10 the second-filed action to halt final approval of the settlement until the court in the second-filed
 11 action could rule on the plaintiffs’ motion to intervene and transfer. *Id.* at 1354-55. The second-filed
 12 court then transferred the action to the Middle District of Georgia where *Perkins* was pending under
 13 the first-to-file rule. *See Boren v. American National Ins. Co.*, Case No. 1:06-CV-00294, ECF No.
 14 44 (W.D. Tex.). This is exactly the relief Plaintiffs have petitioned for here. *See Hodes Action*, ECF
 15 No. 9 at 16.¹

16 *Managed Care* and *Perkins* are just two examples where courts have resorted to the All Writs
 17 Act to curb a defendant’s efforts to settle claims in consolidated proceedings (and defeat jurisdiction)
 18 with different counsel in a separate, later-filed action. *See In re Checking Acct. Overdraft Litig.*, 859
 19 F. Supp. 2d 1313, 1322 (S.D. Fla. 2012) (enjoining defendant’s “efforts to settle a copycat case and
 20 thereby deprive this Court of its ability to adjudicate” the matter); *In re Am. Online Spin-Off Accts.*
 21 *Litig.*, 2005 WL 5747463, at *2, 4-5 (C.D. Cal. May 9, 2005) (enjoining defendant under the All
 22 Writs Act from proceeding with the settlement in a separate action that “it secretly negotiated”
 23 because the conduct “diminishes this Court’s ability to bring the [present MDL case] to a natural
 24 conclusion.”); *In re Bank of Am. Wage & Hour Emp. Litig.*, 740 F. Supp. 2d 1207, 1216-18 (D. Kan.
 25

26 ¹ GoodRx argues that an injunction is not necessary because Plaintiffs have already filed a motion to
 27 intervene in *Hodes*. *See Opp.* at 6 n. 2. This misses the point. *Perkins* required a stay of the action
 until the court in the later-filed case where the approval motion was pending could rule on the motion
 and send that case back to the first-filed court. *See Perkins*, 446 F. Supp. 2d at 1354-55. The same
 relief is warranted here.

1 2010) (enjoining defendant from issuing settlement notice in overlapping action after failing to
 2 disclose it to the court overseeing the consolidated proceedings or to JPML that needed to decide
 3 whether it should be consolidated in the first instance); *see also Kiland v. Bos. Sci. Corp.*, 2011 WL
 4 1261130, at *7 (N.D. Cal. Apr. 1, 2011) (granting preliminary injunction to enjoin the defendants
 5 from pursuing the second-filed action under the first-to-file rule).

6 Here, an injunction is especially warranted given the indicia of bad faith, rule violations, and
 7 efforts to rush through approval and notice of the *Hodges* settlement in a different district. *See*
 8 Section II, above; *see In re Checking Acct.*, 859 F. Supp. 2d at 1324 (issuing injunction and
 9 admonishing defendant who, after knowing of hearing on motion to enjoin, “rushed to give notice of
 10 their proposed settlement instead of awaiting a ruling from this Court”). GoodRx and Milberg’s
 11 motion to temporarily stay the settlement deadlines pending the court-ordered mediation in January
 12 is an incomplete and inadequate remedy. GoodRx’s conduct makes clear that—while ordered to
 13 attend mediation with Interim Class Counsel—it fully intends to continue to pursue the *Hodges*
 14 settlement if (and as soon as) these efforts fail.² As in *Perkins*, this Court should ensure the stay
 15 GoodRx and Milberg voluntarily sought continues through the mediation until the *Hodges* court can
 16 rule on Interim Class Counsel’s motion to intervene.

17 GoodRx seeks to sow uncertainty about this Court’s authority to issue an injunction by
 18 arguing that some of the cases that have issued an injunction under the All Writs Act involve
 19 consolidation ordered by the Judicial Panel on Multidistrict Litigation (“JPML”) (Opp. at 13), as
 20 opposed to other means of consolidating actions in that forum.³ This is a distinction without a
 21 difference. The JPML exists for the purpose of consolidating overlapping actions as a “last solution”
 22 where the parties have shown they are unable to “informal[ly] coordinat[e]” or doing so is not
 23

24 ² Unfortunately, GoodRx has every incentive to ensure this happens so it can continue to pursue
 25 approval of the ultra-low-cost Florida settlement while complying with the Court’s order.

26 ³ GoodRx’s claim that there is a material distinction between enjoining state and federal court
 27 proceedings is incorrect. Simply because the need to resort to the All Writs Act presents itself more
 often with tag-along state court proceedings does not make it improper to utilize the same tools when
 a settlement is reached in a tag-along federal action. *See Managed Care*, 236 F. Supp. 2d at 1339.
 Indeed, the reason this occurs *less often* in sister jurisdictions is because of procedural safeguards,
 like the first-to-file rule, which prevent duplicative cases from existing in multiple jurisdictions.

1 “feasible.” *In re: Geico Customer Data Sec. Breach Litig.*, MDL No. 3013, ECF No. 33 at 2. Here,
 2 resorting to the JPML was unnecessary (and would have been wasteful) because the action filed
 3 **outside** this District informally agreed to dismiss their lawsuit and proceed in this forum where the
 4 actions were then consolidated.⁴ That Plaintiffs were able to achieve the same result without
 5 petitioning the JPML does not change the analysis. The fact remains that this is a consolidated action
 6 where, pursuant to the first-to-file rule, any later actions would be transferred and subsumed within
 7 the existing case, *i.e.*, the same as any action consolidated by the JPML.⁵ Thus, the reasoning in
 8 *Managed Care, Checking Account, American Online, and Bank of America* applies with equal force
 9 here.

10 **IV. THIS IS NOT A CASE OF PARALLEL LITIGATION**

11 Faced with precedent admonishing (and enjoining) defendants who have sought to settle
 12 claims in consolidated proceedings in a different forum, GoodRx attempts to analogize this case to
 13 actions involving genuine “parallel” proceedings. This is wrong for two reasons.

14 First, this is not an instance of parallel litigation. Parallel litigation involves multiple cases
 15 with overlapping or similar claims proceeding at the same time. When claims are fully duplicative
 16 of one another, procedural safeguards exist to ensure the same cases are not litigated in multiple
 17 forums, such as informal coordination (*i.e.*, having cases refiled in the same forum, like Interim Class
 18 counsel did here with respect to the action filed in the Southern District of New York), transfer
 19 pursuant to the first-to-file rule, 28 U.S.C. § 1404, or as a last resort, through the JPML and 28 U.S.C.
 20 § 1407. While any of these measures would have ensured *Hodes* was transferred here and
 21 consolidated with the existing litigation, GoodRx and Milberg bypassed these rules by concealing
 22 the existence of this action from the *Hodes* court, and the existence of the *Hodes* action from this
 23 one, while rushing for preliminary approval. GoodRx cannot violate the Local Rules and their notice

24
 25 ⁴ See *E.C. v. GoodRx Holdings, Inc.*, 1:23-cv-00943 (S.D.N.Y.).

26 ⁵ The mechanism for achieving transfer is also procedurally similar. Had Interim Class Counsel been
 27 provided notice of the *Hodes* action they could have sought transfer immediately under the first-to-
 file rule, or alternatively 28 U.S.C. § 1404, by filing a motion in the later-filed action. In an MDL,
 plaintiffs would file a notice of tag-along action that would alert the JPML of a newly filed action,
 and effectuate transfer under 28 U.S.C. § 1407. The end result is the same.

1 requirements to avoid being transferred and consolidated and then simultaneously assert the action
 2 in *Hodges* is actually “parallel,” justifying separate settlement discussions.⁶

3 Second, even in instances of “parallel” litigation (which this is not) courts still consider an
 4 injunction appropriate where there is evidence of collusion, a reverse auction, or other “odor of
 5 mendacity.” *See* Opp. at 6 (citing *Negrete v. Allianz Life Ins. Co. of N. Am.*, 523 F.3d 1091 (9th Cir.
 6 2008)). All are present here. GoodRx misrepresented its intent to mediate to Interim Class Counsel, this
 7 Court, and the court-appointed mediator to delay (and ultimately avoid) court-ordered mediation that
 8 should have occurred months ago. It *simultaneously* engaged in separate mediations with its chosen
 9 counsel who had no action pending and entered a settlement that, on its face, resulted in an
 10 unreasonable discount that allows GoodRx to potentially escape liability for just 0.013% of its actual
 11 exposure. And it then violated the Local Rules to force through the settlement in a completely
 12 different forum in hopes of avoiding detection.

13 Not a single case GoodRx cites (including *Negrete*) endorse these kinds of tactics. *See* Opp.
 14 at 9 (citing *Negrete*, 523 F.3d 1095-99 (refusing to enjoin settlement efforts in three of five
 15 overlapping or similar “parallel” cases where there was no evidence of collusion or a reverse auction,
 16 or any other “odor of mendacity”); *Mandel v. Grande Cosms., LLC*, 2023 WL 7109893, at *2 (N.D.
 17 Cal. Oct. 27, 2023) (denying request for injunction under All Writs Act where there were no facts
 18 demonstrating collusive conduct or a reverse auction);⁷ *Primo v. Pac. Biosciences of California, Inc.*,
 19 2013 WL 4482739, at * 3 (N.D. Cal. Aug. 20, 2013) (declining to enjoin the first filed action from
 20 proceeding with settlement, not a subsequent case); *Saleh v. Titan Corp.*, 353 F. Supp. 2d 1087, 1094
 21 (S.D. Cal. 2004) (refusing to enjoin non-parties under All Writs Act in a separate case because it was
 22

23 ⁶ Nor is *Hodges* “parallel” as it was only filed to effectuate the settlement between Hodges’s counsel
 24 and GoodRx.

25 ⁷ *Mandel* (and the similar, later-filed action pending in New Jersey, *Nixon v. Grande Cosms., LLC*,
 26 No. 1:22-cv-06639 (D. N.J.)) are evidence of how actions typically proceed when one or more similar
 27 cases are filed in multiple districts. The *Mandel* Action was filed first, and when the plaintiffs in
Nixon sought preliminary approval, the court admonished plaintiffs for seeking an “end-run around
 the *Mandel* Court’s jurisdiction” and refused to rule on the preliminary approval motion until it was
 clear “all efforts to settle [the *Mandel* Action] . . . have not been successful.” *See Nixon*, ECF No.
 27. Thus, the *Nixon* Court had righted this wrong before the *Mandel* Court declined to exercise its
 powers under the All Writs Act.

1 not proceeding as a class action and therefore presented no “detriment[]” to the existing class case);
 2 *In re Life Invs. Ins. Co. of Am.*, 589 F.3d 319, 328 (6th Cir. 2009) (reversal of an injunction where
 3 pending matter was one of “several cases pending in various state and federal courts” some of which
 4 were “initiated before” the existing matter); *Grider v. Keystone Health Plan Cent., Inc.*, 500 F.3d
 5 322, 326 (3d Cir. 2007) (plaintiff in the “tag-along” action sought to enjoin settlement in a
 6 consolidated MDL that was “nearly three years old”). And for good reason: if this were the law, all
 7 defendants would disregard consolidation orders, class certification, and leadership appointment to
 8 shop for counsel willing to file an action and settle at the lowest price.

9 **V. GOODRX WAS COMPELLED TO NEGOTIATE SETTLEMENT WITH INTERIM
 CLASS COUNSEL**

10 GoodRx dedicates a substantial portion of its opposition to a high-level overview of Rule
 11 23(g) appointment, arguing that an order under this Rule cannot be enforced beyond the “appointing
 12 court.” Opp. at 10. However, this ignores that Rule 23(g), like all Federal Rules, does not operate in
 13 isolation, but achieves its nationwide effect by working in concert with other procedural devices
 14 available in Federal Courts. Transfer procedures—like the first-to-file rule Plaintiffs seek to enforce
 15 in Florida—are particularly relevant here as they operate to give nationwide effect to the Court’s
 16 leadership order by providing a means to bring the *Hodges* case (and any other related actions) to
 17 this District.⁸ This, of course, makes good sense as it helps avoid wasting judicial resources on
 18 duplicative litigation in different forums and inconsistent results across courts dealing with the same
 19 issues.

20 Not surprisingly, the first-to-file rule creates a universally recognized “strong presumption
 21 across the federal circuits that favors the forum of the first-filed suit.” *Oceana Seafood Prod., LLC*
 22 v. *Louisiana Newpack Shrimp Co.*, 2020 WL 13880993, at *2 (S.D. Fla. Dec. 31, 2020) (citing
 23 *Manuel v. Convergys Corp.*, 430 F.3d 1132, 1135 (11th Cir. 2005)); *Hansell v. TracFone Wireless,*
 24 *Inc.*, 2013 WL 6155618, at *4 (N.D. Cal. Nov. 22, 2013) (“The first-to-file rule creates a presumption

26
 27 ⁸ This is significant as even GoodRx admits that when “all related cases [are] already before the same
 court” the defendant should be “compelled” to “only negotiate with interim counsel.” See Opp. at 11
 n. 6 (citing *Salmonson v. Bed Bath & Beyond, Inc.*, 2012 WL 12919187 at * 5 (C.D. Cal. Apr. 27,
 2012)).

1 that favors venue in this district.”). GoodRx cites two cases evaluating the application of the first-to-
 2 file rule, *neither of which* support its assertion that an action filed for the purpose of effectuating a
 3 settlement with different counsel defeats the presumption.⁹ See Opp. at 14 (citing *Pacesetter Sys., Inc. v. Medtronic, Inc.*, 678 F.2d 93, 95 (9th Cir. 1982) (affirming district court’s application of the
 4 first-to-file rule); *Alltrade, Inc. v. Uniweld Prods., Inc.*, 946 F.2d 622, 628 (9th Cir. 1991) (same)).

5 The malintent of GoodRx’s failure to notify the Florida court of this Action crystalizes against
 6 this backdrop. Knowing that the first-to-file rule would require transfer here regardless of which
 7 federal court *Hodes* was eventually filed in, the notice violation is a clear attempt to avoid this
 8 Court’s order on the appointment of lead counsel. This should not be allowed.¹⁰

10 VI. AN INJUNCTION IS NECESSARY TO PRESENT IRREPARABLE HARM

11 GoodRx’s conduct in usurping this Court’s jurisdiction has clearly prejudiced Plaintiffs and
 12 Class members, forcing a choice between two equally bad options: (1) opting-out of the *Hodes*
 13 settlement and seeking to litigate their claims on an individual basis, an option *Hodes* plaintiffs
 14 themselves recognize would be fruitless given the costs of doing so¹¹; or (2) accepting a nominal
 15 amount (78 cents) for claims *Hodes* plaintiffs’ counsel valued in the hundreds of dollars. GoodRx’s
 16 suggestion that opting out or appearing at a fairness hearing are adequate remedies cannot be
 17 reconciled with these facts, as neither can undo the harm already done.¹²

18

19 ⁹ GoodRx relies almost exclusively on cases approving settlements in parallel litigation. As described
 20 in Section IV, this is not an instance of parallel cases.

21 ¹⁰ GoodRx’s separate claim that deviation from the first-to-file rule is appropriate because *Hodes*
 22 has “progressed” further than this action is absurd. Opp. at 14. Were this the measure of “progress”
 23 interlopers could show up on the eve of trial to settle the claims in an action they were never a part
 24 of and claim “priority” because they had resolved those claims. GoodRx’s argument is also factually
 inaccurate. Far from the “very early stage of litigation” (Opp. at 14) this case has proceeded through
 consolidation, appointment of interim lead counsel, and briefing on several motions to dismiss,
 motions to compel and/or stay, document and deposition discovery, as well as motions to exclude
 evidence. There is no indication in any of the *Hodes* papers that counsel there did similar work.

25 ¹¹ See *Hodes* Action, ECF No. 7 at 28 (“[M]embers of the Class would have little interest in pursuing
 26 their own separate actions” because of “the cost of litigating complex[] legal issues against a
 relatively large corporate entity[.]”)

27 ¹² Even sending *notice* presents the potential to cause irreparable harm, as it would cause confusion
 among class members. See *In re Bank of Am. Wage & Hour Emp. Litig.*, 740 F. Supp. 2d 1207, 1218
 (D. Kan. 2010) (explaining opt-out rights or raising objections at fairness hearing do not negate
 “irreparable harm” caused by proposed settlement in previously undisclosed tag-along action

1 This prejudice is especially evident now that this Court has re-ordered the parties to
 2 mediate—something that would have occurred months ago under Judge Chhabria’s order if GoodRx
 3 had not deceived Interim Class Counsel and this Court. Plaintiffs expect GoodRx to use the *Hodges*
 4 settlement as an artificial cap on Plaintiffs’ and the Class’s claims that do not align with GoodRx’s
 5 actual liability. *See* Section VII.D. If GoodRx is not enjoined from pursuing the *Hodges* settlement,
 6 it has no incentive to mediate in good faith or negotiate a fair settlement in this action that is within
 7 the actual range of its exposure. *See Managed Care*, 236 F. Supp. 2d at 1345 (finding “irreparable
 8 harm” where the settlement reached outside the consolidated proceedings “will have the practical
 9 effect of limiting and hindering settlement of the encompassing issues before this Court, and of
 10 impeding the mediation already ordered by this Court.”).

11 Lastly, not only will allowing GoodRx to proceed with the settlement cause irreparable harm
 12 for the claims against GoodRx, but those against the remaining defendants. The practical effect of
 13 GoodRx’s conduct, should it be allowed to continue, would be an endorsement to every defendant
 14 to seek out separate counsel to resolve the allegations against it at a discount in a different forum or
 15 outside the federal court system altogether. *Managed Care*, 236 F. Supp. 2d at 1344 (“if [the Court]
 16 were to let [the defendant] proceed in this manner, nothing would stop every other Defendant from
 17 following suit. They would each settle their claims in a state or federal court outside this Court’s
 18 jurisdiction.”).¹³

19 VII. THE *HODGES* SETTLEMENT IS NOT FAIR AND REASONABLE

20 If anything is “divorced from reality” (Opp. at 3) it is GoodRx’s claim that the *Hodges*
 21 settlement is “reasonable, fair, and adequate.” Opp. at 15. Both the means of accomplishing the
 22 settlement—and its end result—indicate it bears no resemblance to the types of settlements courts
 23 find fair, reasonable, and adequate for these claims.

24 because even sending “notice” could “deter participation” in the consolidated action as some class
 25 members would believe their “claims were resolved”).

26 ¹³ *Utne v. Home Depot U.S.A., Inc.*, 2022 WL 1443339, at *4–5 (N.D. Cal. May 6, 2022) is
 27 distinguishable. That case was evaluating a motion for sanctions, not a motion to enjoin and, in any
 event, the defendant was seeking to settle different claims than the ones implicated in the current
 case. To ensure it was acting in good faith, the defendant had voluntarily offered to stay the second
 action and also commit *not to settle the claims* at issue in *Utne* in any other action.

1 **A. GoodRx Lied to This Court to Delay Court-Ordered Mediation**

2 This consolidated case was referred to court-sponsored mediation in April 2023, nearly **seven**
 3 **months ago.** *See* ECF No. 81. On May 18, 2023, two days before a pre-mediation conference call
 4 was scheduled, GoodRx began its efforts to delay mediation starting with a phone call to Interim
 5 Class Counsel stating it would not be successful at this stage of the litigation. Fiorilla Decl. at ¶ 5. It
 6 continued to push the narrative that mediation was premature, relaying the same opinion to the court-
 7 ordered mediator and this Court. *See* ECF No. 117; November 14, 2023 Transcript at 7:2-9 (“what
 8 you represented to the mediator and what you represented to me was that it was too early to talk
 9 settlement. Clearly not the case . . . You all were clearly ready to talk settlement, so I know you
 10 didn’t need those motions resolved.”). These representations were false and, ultimately, successful.
 11 As a result of GoodRx’s conduct, court-ordered mediation was delayed until after the parties
 12 completed time-consuming briefing on GoodRx’s motions to dismiss and compel arbitration.

13 **B. GoodRx Simultaneously Pursued Mediation with *Hedges* Counsel**

14 While GoodRx and Milberg both emphasize that Milberg had retained arbitration clients
 15 around March 2023 (ECF No. 165 ¶ 4; *Hedges*, ECF No 4-1 at 7)—through catchy advertisements
 16 promising individual monetary damages worth hundreds of dollars—neither GoodRx nor Milberg
 17 claim any arbitrations were **actually filed**. Neither admits to **when** they first began to discuss
 18 settlement of these arbitration claims. And neither indicates **when** or **who** transformed these
 19 negotiations from a resolution of arbitration-based claims (if that ever was the focus) to the Class’s
 20 claims in this consolidated action.

21 Putting aside these omissions, it is clear GoodRx and Milberg both agreed to mediate and
 22 settle the Class’s claims, despite Milberg not representing any class at that time. This mediation
 23 occurred on July 13, 2023¹⁴, as week after Interim Class Counsel were appointed and, ironically, the
 24 same day this Court entered a stipulation *to extend the deadline* for the parties in this Action to
 25 complete court-ordered mediation. *See* ECF No. 121. If GoodRx’s settlement efforts were truly

26 ¹⁴ It appears Milberg and GoodRx have different recollections of their own settlement negotiations,
 27 with GoodRx asserting the parties attended a full day mediation session on July 13, 2023 and again
 28 on August 11, 2023 (ECF No. 165 at 1) and Milberg claiming the first mediation occurred on August
 29 11, 2023, and that a “second mediation was held” after the fact. *Hedges* Action, ECF No. 4-1 at 7-8.

1 above board, it does not make sense why GoodRx went to such lengths to *avoid* discussing settlement
 2 with Interim Class Counsel and chose to do so with attorneys who did not have any action pending.

3 **C. GoodRx & Milberg's Mediation Was Designed to Quickly Resolve the Class's
 4 Claims Without Engaging in Informed Discussions**

5 Perhaps the most shocking, it appears GoodRx and Milberg negotiated the settlement without
 6 discovery or any information outside the public record. Neither GoodRx or Milberg claim to have
 7 exchanged any documents or information to inform their settlement discussions, relying entirely on
 8 the parties "brief[ing] [of] relevant issues." ECF No. 165 ¶ 5; *Hodes*, ECF No. 4-1 at 7 (asserting
 9 Milberg "researched" the claims and theories). It is unclear how GoodRx can assert these
 10 negotiations were "hard-fought" and "arms-length" (ECF No. 165 ¶ 7) when *no information was
 11 exchanged*, including key details like (1) how many individuals were actually impacted by
 12 GoodRx's conduct; (2) how long GoodRx's conduct persisted; (3) how many third parties GoodRx
 13 disclosed Class members' sensitive health data to; and (4) how this data was used.

14 For instance, while Milberg asserts in its motion for preliminary approval that "there are more
 15 than 16.7 million Class Members" this figure is apparently based on nothing more than the number
 16 of "users of [GoodRx's] Website." *Hodes* Action, ECF No. 4 at 25. Even if this were an acceptable
 17 proxy for *website users* whose health information was disclosed, the Class here (and the Class
 18 *Hodes* seeks to settle) includes all individuals "who used any website, *app, or service* made
 19 available by or through GoodRx at any point prior to October 27, 2023." *Id.* at 12. Interim Class
 20 Counsel is aware of no decision finding a settlement to be fair and reasonable when there is no
 21 exchange of necessary information, including how many individuals (or a reasonable estimate) were
 22 impacted in the first place and fall within the Class.

23 The failure to disclose the most basic facts makes clear there is nothing "arms-length" or
 24 "fair" about the settlement. Rather, it was negotiated with two goals in mind: (1) for GoodRx to settle
 25 the Class's claims as low as possible; and (2) for Milberg to obtain a windfall in attorneys' fees.

26 GoodRx attempts to remedy these glaring deficiencies by pointing to the involvement of a
 27 mediator. *See* Opp. at 3, 17. But using a mediator does not, by itself, demonstrate that a settlement is
 the result of an arms-length negotiation. *In re Bluetooth Headset Prod. Liab. Litig.*, 654 F.3d 935,

1 948 (9th Cir. 2011) (“the mere presence of a neutral mediator . . . is not on its own dispositive of
 2 whether the end product is a fair, adequate, and reasonable settlement agreement.”). The thin veneer
 3 of mediation is even less convincing here, given the lack of information exchanged and drastic steps
 4 GoodRx and Milberg took to (1) hide its settlement efforts; (2) delay settlement in this action; and
 5 (3) avoid transfer once *Hodes* was filed by violating the Local Rules.

6 **D. The Settlement is Untethered to GoodRx’s Liability**

7 As explained in Plaintiffs’ opening motion, courts in this District routinely look to
 8 defendant’s actual exposure in evaluating whether a settlement is adequate. *See* Opening Br. at 6
 9 (citing *Kabasele v. Ulta Salon, Cosms. & Fragrance, Inc.*, 2023 WL 2918679, at *3 (E.D. Cal. Apr.
 10 12, 2023) (rejecting settlement that represents just 5.7% of maximum possible recovery)). The
 11 *Hodes* settlement releases GoodRx from liability for just 0.013% the maximum possible recovery
 12 under Milberg’s conservative (and baseless) estimate of the Class size.¹⁵ While GoodRx claims there
 13 are perceived weaknesses in Plaintiffs’ claims, like its untested statute of limitations defense, it does
 14 not explain how that would warrant a 99.9% haircut at settlement. This is because such a massive
 15 discount can rarely, if ever, be justified. It certainly has not been here.

16 **E. GoodRx & Milberg Violated the Local Rules to Obtain Preliminary Approval**

17 Lastly, even if there was nothing improper with the settlement, there is no explaining why
 18 GoodRx and Milberg violated the Local Rules in order to rush preliminary approval.

19 GoodRx and Milberg repeatedly emphasize that they are represented by experienced and
 20 sophisticated counsel. *See* ECF No. 159 at 2 (GoodRx referring to Milberg as one of the “largest and
 21 most active data privacy plaintiffs’ firms); *Hodes* Action, ECF No. 14 at 5 (Milberg referring to
 22 Kirland as “one of the largest and most feared defense firms in the country”). Sophisticated counsel
 23 at the largest firms in the country know how to comply with the Local Rules. They are also familiar
 24 with the first-to-file rule, which would have required *Hodes*—wherever it was filed in the country—
 25 to be transferred and consolidated with the existing consolidated cases the outset.

26

¹⁵ GoodRx’s reliance on *Maree v. Deutsche Lufthansa AG*, No. 8:20-cv-00885 (C.D. Cal.) as
 27 somehow endorsing its conduct here is a red herring. Bursor filed *Maree* one day after another firm
 had filed a similar action—Bursor did not engage in secret settlement discussions when it had no
 action pending.

Nevertheless, GoodRx and Milberg refused to comply with these rules and otherwise disguised their conduct to avoid detection and transfer to this Court, including by: (1) misrepresenting GoodRx’s willingness to engage in settlement discussions to delay court-ordered mediation; (2) filing *Hedges* as unrelated to any other action; (3) moving for preliminary approval as “unopposed” when it was not; (4) failing to meet and confer with Interim Class Counsel before moving for preliminary approval; (5) omitting any reference to this action in the preliminary approval papers; and (6) failing to file a Notice of Pendency of Related Action in this case.

A six-step scheme cannot be characterized as accidental or mere oversight, and it begs the question why they would go to such lengths if their conduct was not improper.

CONCLUSION

For the foregoing reasons, Plaintiffs' request that this Court retain its jurisdiction and take all steps necessary to that end, including entering an order: (1) requiring GoodRx to cease litigation of, or alternatively file a motion to stay, the *Hodges* action under the first-to-file rule; and (2) prohibiting GoodRx from seeking settlement with non-appointed counsel in violation of the Court's Appointment Order should be granted.

Dated: November 22, 2023

BURSOR & FISHER, P.A.

/s/ *L. Timothy Fisher*

L. Timothy Fisher (SBN 191626)
Jenna L. Gavenman (SBN 348510)
1990 North California Blvd., Suite 940
Walnut Creek, CA 94596
Telephone: (925) 300-4455
Facsimile: (925) 407-2700
E-mail: ltfisher@bursor.com
E-mail: jgavenman@bursor.com

Interim Co-Lead Counsel

Christian Levis (*pro hac vice*)
Amanda Fiorilla (*pro hac vice*)
Rachel Kesten (*pro hac vice*)
LOWEY DANNENBERG, P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601

Telephone: (914) 997-0500
Facsimile: (914) 997-0035
clevis@lowey.com
afiorilla@lowey.com
rkesten@lowey.com

Interim Co-Lead Counsel

Robert C. Schubert #62684
Willem F. Jonckheer #178748
Amber L. Schubert #278696
SCHUBERT JONCKHEER & KOLBE LLP
2001 Union Street, Suite 200
San Francisco, CA 94123
Tel: (415) 788-4220
Fax: (415) 788-0161
rschubert@sjk.law
wjonckheer@sjk.law
ascubert@sjk.law

Mark L. Javitch (CA SBN 323729)
mark@javitchlawoffice.com
JAVITCH LAW OFFICE
3 East 3rd Ave., Suite 200
San Mateo, CA 94401
Telephone: (650) 781-8000
Facsimile: (650) 648-0705

Thomas A. Zimmerman, Jr. (*pro hac vice*)
tom@attorneyzim.com
ZIMMERMAN LAW OFFICES, P.C.
77 W. Washington Street, Suite 1220
Chicago, Illinois 60602
Telephone: (312) 440-0020
Facsimile: (312) 440-4180

Israel David (*pro hac vice*)
israel.david@davidllc.com
Blake Hunter Yagman (*pro hac vice*)
blake.yagman@davidllc.com
ISRAEL DAVID LLC
17 State Street, Suite 4010
New York, New York 10004
Telephone: (212) 739-0622
Facsimile: (212) 739-0628

Rebecca M. Hoberg
rhoberg@moyalawfirm.com
MOYA LAW FIRM
1300 Clay Street, Suite 600
Oakland, California 94612
Telephone: (510) 926-6521

1 Jonathan Shub #237708
2 Benjamin F. Johns (*pro hac vice* forthcoming)
3 Samantha E. Holbrook (*pro hac vice* forthcoming)
4 **SHUB & JOHNS LLC**
5 200 Barr Harbor Drive, Suite 400
6 Conshohocken, PA 19428
7 Phone: (610) 585-1195
8 jshub@shublawyers.com
9 bjohns@shublawyers.com
10 sholbrook@shublawyers.com